Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer.
Randomised studies in locally advanced cervical cancer patients showed that cisplatin should be given concurrently with radiotherapy, because of a better long-term survival compared to radiotherapy alone. This increases the relevance of treatment related toxicity. This review summarises the acute and long-term toxicity of radiotherapy given with or without chemotherapy for cervical cancer. Acute toxicity (all grades) of radiotherapy is reported in 61% of the patients in the rectosigmoid, in 27% as urological, in 27% as skin and in 20% as gynaecological toxicity. Moderate and severe morbidity consists of 5% to 7% gastrointestinal and 1% to 4% genitourinary toxicity. Adding chemotherapy to radiotherapy increases acute haematological toxicity to 5% to 37% of the patients and nausea and vomiting in 12% to 14%. Late effects of radiotherapy include gastrointestinal, urological, female reproductive tract, skeletal and vascular toxicity, secondary malignancies and quality of life issues. For at least 20 years after treatment, new side effects may develop. Gastrointestinal toxicity usually occurs in the first 2 years after treatment in about 10% of the patients. The incidence of moderate and severe urological toxicity can increase up to 10% and rises over time. Gynaecological toxicity usually occurs shortly after treatment while skeletal and vascular toxicity can occur years to decades later. Thus far, no increase in late toxicity has been observed after the addition of cisplatin to radiotherapy. Finally, methods to prevent or decrease late toxicity and therapeutical options are discussed. However, most randomised studies still have a limited follow-up period.
Maduro
J H
JH
Department of Radiotherapy, University Hospital Groningen, Groningen, The Netherlands.
Pras
E
E
Willemse
P H B
PH
de Vries
E G E
EG
D000970:Antineoplastic Agents / Q000009:adverse effects*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004064:Digestive System / Q000528:radiation effects; D005260:Female; D050723:Fractures, Bone / Q000209:etiology; D006801:Humans; D016609:Neoplasms, Second Primary / Q000209:etiology; D011788:Quality of Life; D011878:Radiotherapy / Q000009:adverse effects*; D011879:Radiotherapy Dosage; D014566:Urogenital System / Q000528:radiation effects; D002583:Uterine Cervical Neoplasms / Q000628:therapy*; D014652:Vascular Diseases / Q000209:etiology
D000970:Antineoplastic Agents